Quantum BioPharma sees cash runway beyond March 2027

“We have finished the third quarter of 2025 in a stronger position than at close of Q2 2025. The third quarter of 2025 was highlighted by a significant reduction in total liabilities, increase in shareholder equity, continued delivery of efficiencies, and continued development of our robust pipeline of products and assets focused on addressing significant unmet needs in brain disorders and alcohol health, with three potential near-term monetization events” said Donal Carroll, CFO. “Unbuzzd Wellness, licensee of our rapid alcohol detoxification beverage unbuzzd, has launched a Reg D financing for up to $5M to capitalize a possible go public transaction. This will provide non-dilutive cash to Quantum through monetization of our holding in a controlled and strategic fashion. Quantum BioPharma’s equity in Unbuzzd Wellness will not get diluted with this financing. Also, in Q3, Health Canada granted a Product License for natural health product Qlarity that Enhances Energy and Promotes Metabolism, Mental Alertness and Cognitive Performance permitting Quantum to sell the product in Canada. We also made significant progress with our MS program. Our announced partnership with Massachusetts General Hospital scientists is underway with the first patient having undergone PET scanning in Q3 utilizing a potentially breakthrough diagnostic protocol for monitoring demyelination related to MS. Lucid-MS is a first-in-class, non-immunomodulatory, orally administered compound demonstrating neuroprotection in animal studies for the treatment of MS. It is a patented New Chemical Entity that has a unique mechanism of action. Lucid-MS was deemed safe and well-tolerated by healthy participants by the Safety Review Committee, and we are optimistic about the potential of Lucid-MS to protect myelin in MS patients as it represents a new direction in the treatment of this disease. We are now looking ahead to our Phase 2 trial as we work towards our goals of drug approval and commercialization. Operationally, we continue to strengthen our balance sheet and expand our reach in the capital markets to execute on upcoming milestones. Over the last several months, we have continued to purchase and sell Bitcoin and other cryptocurrencies as part of our strategic efforts, reflecting our belief in the potential of cryptocurrencies to provide a return on investment for our shareholders and to provide some hedge against the dollar. We currently have significant profits in our crypto portfolio of $572,000, which consists largely of Bitcoin and some other crypto currencies, and we continue to manage our treasury risk with this diversification. Looking ahead, we are focused on managing our balance sheet to be in an even stronger financial position. We believe we now have sufficient cash to maintain basic operations beyond March 2027.”